Clinical Trial Detail

NCT ID NCT02927301
Title A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer (NSCLC)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Genentech, Inc.
Indications

lung non-small cell carcinoma

Therapies

Atezolizumab

Age Groups: senior adult

No variant requirements are available.